Gordon J Freeman

List of Publications by Year in Descending Order

420 papers	87,822 citations	150 h-index	293 g-index
458 ext. papers	102,138 ext. citations	13 avg, IF	7.86 L-index

#	Paper	IF	Citations
420	Anti-CAIX BBζCAR4/8 Tcells exhibit superior efficacy in a ccRCC mouse model.. *Molecular Therapy - Oncolytics*, **2022**, 24, 385-399	6.4	2
419	Soluble PD-L1 as an early marker of progressive disease on nivolumab. **2022**, 10,		3
418	Loss of sensitizes immune checkpoint blockade in non-small cell lung cancer.. *Science Advances*, **2022**, 8, eabi9533	14.3	2
417	The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings.. *Frontiers in Immunology*, **2022**, 13, 773946	8.4	2
416	USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy.. *Nature Communications*, **2022**, 13, 1700	17.4	3
415	Insights into immune escape during tumor evolution and response to immunotherapy using a rat model of breast cancer.. *Cancer Immunology Research*, **2022**,	12.5	1
414	Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. *Cancer Immunology Research*, **2021**, 9, 1465-1475	12.5	0
413	PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. *Journal of Experimental Medicine*, **2021**, 218,	16.6	47
412	VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy. *Trends in Immunology*, **2021**, 42, 209-227	14.4	11
411	Inhibitory CD161 receptor identified in glioma-infiltrating Tcells by single-cell analysis. *Cell*, **2021**, 184, 1281-1298.e26	56.2	55
410	Emerging concepts in PD-1 checkpoint biology. *Seminars in Immunology*, **2021**, 52, 101480	10.7	19
409	ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. *Nature Cancer*, **2021**, 2, 503-514	15.4	18
408	Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates. *Mucosal Immunology*, **2021**, 14, 1055-1066	9.2	4
407	Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. *Molecular Cell*, **2021**, 81, 2317-2331.e6	17.6	23
406	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. *Clinical Cancer Research*, **2021**, 27, 276-287	12.9	40
405	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. *Cancer Immunology Research*, **2021**, 9, 156-169	12.5	20
404	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. *Clinical Cancer Research*, **2021**, 27, 1371-1380	12.9	18

403	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. *Blood*, **2021**, 137, 1353-1364	2.2	11
402	PD-1 blockade exacerbates infection in rhesus macaques. *Science Immunology*, **2021**, 6,	28	17
401	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. *Science Translational Medicine*, **2021**, 13,	17.5	22
400	Association of with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment. *Clinical Cancer Research*, **2021**, 27, 2816-2826	12.9	12
399	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. *Cancer Discovery*, **2021**, 11, 1524-1541	24.4	13
398	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. *Haematologica*, **2021**, 106, 1330-1342	6.6	4
397	PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8 T cells in lymphoid tissue. *Science Immunology*, **2021**, 6, eabh3034	28	4
396	Inactivation of Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. *Cancer Discovery*, **2020**, 10, 1296-1311	24.4	16
395	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. *Nature Medicine*, **2020**, 26, 909-918	50.5	155
394	Retinoblastoma protein expression and its predictors in triple-negative breast cancer. *Npj Breast Cancer*, **2020**, 6, 19	7.8	9
393	Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. *Communications Biology*, **2020**, 3, 128	6.7	31
392	The importance of exosomal PDL1 in tumour immune evasion. *Nature Reviews Immunology*, **2020**, 20, 209-215	36.5	165
391	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. *Journal of Clinical Oncology*, **2020**, 38, 63-70	2.2	64
390	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. *Cancer Cell*, **2020**, 37, 37-54.e9	24.3	73
389	Epigenetic CRISPR Screen Identifies as an Immunotherapeutic Target in -Mutant Lung Adenocarcinoma. *Cancer Discovery*, **2020**, 10, 270-287	24.4	68
388	Programmed death ligand 2 - A link between inflammation and bone loss in rheumatoid arthritis. *Journal of Translational Autoimmunity*, **2020**, 3, 100028	4.1	5
387	Acidity changes immunology: a new VISTA pathway. *Nature Immunology*, **2020**, 21, 13-16	19.1	6
386	The PD-1 Pathway Regulates Development and Function of Memory CD8 T Cells following Respiratory Viral Infection. *Cell Reports*, **2020**, 31, 107827	10.6	26

385	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. *Genome Biology*, **2020**, 21, 263	18.3	7
384	Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. *Nature Cell Biology*, **2020**, 22, 1064-1075	23.4	57
383	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. *Nature Communications*, **2019**, 10, 4346	17.4	89
382	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. *Clinical Cancer Research*, **2019**, 25, 2174-2184	12.9	47
381	High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer. *Journal of Extracellular Vesicles*, **2019**, 8, 1597603	16.4	56
380	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. *Immunity*, **2019**, 50, 1498-1512.e5	32.3	206
379	Blockade of RGMb inhibits allergen-induced airways disease. *Journal of Allergy and Clinical Immunology*, **2019**, 144, 94-108.e11	11.5	4
378	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. *Cancer Immunology Research*, **2019**, 7, 644-657	12.5	52
377	Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 16971-16980	11.5	61
376	The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018 **2019**, 7, 221		2
375	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. *Clinical Cancer Research*, **2019**, 25, 6080-6088	12.9	33
374	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. *Journal of Clinical Oncology*, **2019**, 37, 4568-4568	2.2	4
373	Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation. *Blood Advances*, **2019**, 3, 3419-3431	7.8	2
372	Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1 Stem-like CD8 T Cells during Chronic Infection. *Immunity*, **2019**, 51, 1043-1058.e4	32.3	150
371	PTPN2 regulates the generation of exhausted CD8 T cell subpopulations and restrains tumor immunity. *Nature Immunology*, **2019**, 20, 1335-1347	19.1	68
370	A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. *Cancer Immunology, Immunotherapy*, **2019**, 68, 421-432	7.4	57
369	Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. *International Journal of Cancer*, **2019**, 144, 2266-2278	7.5	43
368	Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. *Clinical Cancer Research*, **2019**, 25, 290-299	12.9	57

367	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. *Science Advances*, **2018**, 4, eaar2766	14.3	254
366	TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. *OncoImmunology*, **2018**, 7, e1442999	7.2	36
365	Role of PD-1 during effector CD8 T cell differentiation. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4749-4754	11.5	178
364	RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E1475-E1484	11.5	45
363	Modeling tumor immunity of mouse glioblastoma by exhausted CD8 T cells. *Scientific Reports*, **2018**, 8, 208	4.9	16
362	Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function. *Journal of Immunology*, **2018**, 200, 2592-2602	5.3	62
361	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. *Neuro-Oncology*, **2018**, 20, 225-235	1	38
360	LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. *Cell*, **2018**, 174, 549-563.e19	36.2	264
359	Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells. *Journal of Immunology*, **2018**, 201, 971-981	5.3	36
358	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. *Nature Medicine*, **2018**, 24, 1550-1558	50.5	881
357	BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in -Mutant Non-Small Cell Lung Cancer. *Cancer Immunology Research*, **2018**, 6, 1234-1245	12.5	53
356	PD-L1 Binds to B7-1 Only on the Same Cell Surface. *Cancer Immunology Research*, **2018**, 6, 921-929	12.5	77
355	Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. *JCI Insight*, **2018**, 3,	9.9	49
354	Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. *Blood*, **2018**, 132, 1579-1579	2.2	2
353	A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model. *Blood*, **2018**, 132, 1446-1446	2.2	2
352	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. *Journal of Clinical Oncology*, **2018**, 36, 619-619	2.2	2
351	CD160 Stimulates CD8 T Cell Responses and Is Required for Optimal Protective Immunity to. *ImmunoHorizons*, **2018**, 2, 238-250	2.7	11
350	The Two SH2 Domains of SHP-2 Bridge Two PD-1 Molecules Resulting in SHP-2 Activation and PD-1-Mediated Inhibition. *Blood*, **2018**, 132, 862-862	2.2	

349	Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. *Cancer Discovery*, **2018**, 8, 196-215	24.4	228
348	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. *Cancer Discovery*, **2018**, 8, 216-233	24.4	308
347	Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. *Nature*, **2018**, 553, 91-95	50.4	408
346	TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. *JCI Insight*, **2018**, 3,	9.9	26
345	IMMU-19. PD-1 BLOCKADE ACTIVATES CD4 T CELLS AND THE INNATE IMMUNE RESPONSE FOR GLIOBLASTOMA ERADICATION. *Neuro-Oncology*, **2018**, 20, vi125-vi125	1	78
344	PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. *Cell Reports*, **2018**, 25, 2972-2980.e5	10.6	205
343	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. *Immunity*, **2018**, 49, 1148-1161.e7	32.3	352
342	Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. *British Journal of Cancer*, **2018**, 119, 1223-1232	8.7	46
341	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. *Gut*, **2017**, 66, 1463-1473	19.2	115
340	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. *Immunity*, **2017**, 46, 197-204	32.3	288
339	Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. *Science*, **2017**, 355, 1423-1427	33.3	486
338	Anti-Programmed Death 1 (PD1) **2017**, 57-66		1
337	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. *Journal of Thoracic Oncology*, **2017**, 12, 1268-1279	8.9	99
336	In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. *Science Translational Medicine*, **2017**, 9,	17.5	331
335	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. *Journal of Urology*, **2017**, 198, 817-823	2.5	21
334	Labeling Extracellular Vesicles for Nanoscale Flow Cytometry. *Scientific Reports*, **2017**, 7, 1878	4.9	185
333	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. *Cancer Immunology Research*, **2017**, 5, 480-492	12.5	196
332	PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. *Journal of Experimental Medicine*, **2017**, 214, 895-904	16.6	382

331	Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. *Cancer Immunology Research*, **2017**, 5, 1046-1055	12.5	25
330	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. *Journal of Clinical Oncology*, **2017**, 35, 1836-1844	2.2	89
329	Enhancing CD8 T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. *Cancer Cell*, **2017**, 32, 377-391.e9	24.3	253
328	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. *Blood*, **2017**, 130, 2420-2430	2.2	174
327	PD-1 Status in CD8 T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. *Cancer Research*, **2017**, 77, 6353-6364	10.1	111
326	T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. *Nature Communications*, **2017**, 8, 1747	17.4	240
325	New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31Annual Meeting of the Society for Immunotherapy of Cancer, 2016 **2017**, 5, 50		8
324	Immune Escape in Breast Cancer During to Invasive Carcinoma Transition. *Cancer Discovery*, **2017**, 7, 1098-1115	24.4	113
323	Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand interaction. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 1468-1477.e2	11.5	121
322	Extracellular Vesicles Transfer the Receptor Programmed Death-1 in Rheumatoid Arthritis. *Frontiers in Immunology*, **2017**, 8, 851	8.4	18
321	IMMU-10. EXPRESSION OF PD-L2, IN GLIOBLASTOMA; IMPLICATIONS AS A BIOMARKER FOR IMMUNOTHERAPY. *Neuro-Oncology*, **2017**, 19, vi114-vi114	1	78
320	Abstract 572: Inhibition of IDO1 with epacadostat enhances anti-tumor efficacy of PD-1 blockade in a syngeneic glioblastoma (GBM) model **2017**,		4
319	The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. *Journal of Clinical Oncology*, **2017**, 35, 4576-4576	2.2	
318	Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. *Gut*, **2016**, 65, 1973-1980	19.2	454
317	MicroRNA MIR21 and T Cells in Colorectal Cancer. *Cancer Immunology Research*, **2016**, 4, 33-40	12.5	22
316	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. *Scientific Reports*, **2016**, 6, 27702	4.9	38
315	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. *Journal of Clinical Oncology*, **2016**, 34, 2698-704	2.2	677
314	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. *Cancer Immunology Research*, **2016**, 4, 679-87	12.5	54

313	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. *Cancer Research*, **2016**, 76, 999-1008	10.1	297
312	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. *Nature Communications*, **2016**, 7, 10501	17.4	846
311	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. *Immunity*, **2016**, 44, 343-54	32.3	518
310	Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 456-65	9.4	42
309	LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. *Journal of Immunology*, **2016**, 196, 2085-94	5.3	27
308	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. *JAMA Oncology*, **2016**, 2, 518-22	13.4	95
307	Coinhibitory Pathways in Immunotherapy for Cancer. *Annual Review of Immunology*, **2016**, 34, 539-73	34.7	507
306	Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN That Induce PD-L1 Expression in Head and Neck Cancer. *Cancer Research*, **2016**, 76, 1031-43	10.1	193
305	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. *Cancer Immunology Research*, **2016**, 4, 124-35	12.5	236
304	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. *Journal of Clinical Investigation*, **2016**, 126, 2642-60	15.9	63
303	Interaction of Both SH2 Domains of SHP-2 with a PD-1 Homodimer Is Required for PD-1-Mediated Inhibition of T Cell Responses. *Blood*, **2016**, 128, 859-859	2.2	1
302	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. *Journal of Clinical Oncology*, **2016**, 34, e23221-e23221	2.2	1
301	Effect of 5-fluorouracil on membranous PD-L1 expression in colon cancer cells.. *Journal of Clinical Oncology*, **2016**, 34, 592-592	2.2	5
300	Expression of lectin-like transcript-1 in human tissues. *F1000Research*, **2016**, 5, 2929	3.6	11
299	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. *Journal of Clinical Oncology*, **2016**, 34, 4535-4535	2.2	
298	PD-L1 expression in Epstein-Barr virus-infected gastric cancers.. *Journal of Clinical Oncology*, **2016**, 34, 4052-4052	2.2	1
297	Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. *Oncotarget*, **2016**, 7, 32925-32	3.3	191
296	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. *JCI Insight*, **2016**, 1, e87415	9.9	89

295	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. *Oncotarget*, **2016**, 7, 76565-76576	3.3	74
294	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. *Oncotarget*, **2016**, 7, 34341-55	3.3	185
293	Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. *Oncotarget*, **2016**, 7, 17194-211	3.3	62
292	Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. *American Journal of Surgical Pathology*, **2016**, 40, 443-53	6.7	35
291	5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers **2016**, 4, 65		66
290	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in -associated and sporadic triple-negative breast cancer. *Npj Breast Cancer*, **2016**, 2, 16002	7.8	22
289	Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. *Immunity*, **2016**, 44, 955-72	32.3	315
288	Repulsive Guidance Molecule b (RGMb) Is Dispensable for Normal Gonadal Function in Mice. *Biology of Reproduction*, **2016**, 94, 78	3.9	4
287	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. *Journal of Clinical Oncology*, **2016**, 34, 2690-7	2.2	472
286	Learning from PD-1 Resistance: New Combination Strategies. *Trends in Molecular Medicine*, **2016**, 22, 448-451	11.5	52
285	Targetable genetic features of primary testicular and primary central nervous system lymphomas. *Blood*, **2016**, 127, 869-81	2.2	317
284	Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. *Nature*, **2016**, 537, 417-421	50.4	834
283	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. *Clinical Cancer Research*, **2015**, 21, 3031-40	12.9	249
282	Combination cancer immunotherapy and new immunomodulatory targets. *Nature Reviews Drug Discovery*, **2015**, 14, 561-84	64.1	806
281	PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. *Nature Communications*, **2015**, 6, 6692	17.4	554
280	Defective TFH Cell Function and Increased TFR Cells Contribute to Defective Antibody Production in Aging. *Cell Reports*, **2015**, 12, 163-71	10.6	82
279	Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. *Cancer Immunology Research*, **2015**, 3, 1123-1129	12.5	98
278	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. *Blood*, **2015**, 125, 3335-46	2.2	46

277	ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. *Immunity*, **2015**, 42, 538-51	32.3	200
276	A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2. *Clinical Cancer Research*, **2015**, 21, 2201-3	12.9	33
275	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. *Clinical Cancer Research*, **2015**, 21, 3178-86	12.9	23
274	Interferon-□nduced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. *OncoImmunology*, **2015**, 4, e1008824	7.2	184
273	Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. *Journal of Experimental Medicine*, **2015**, 212, 1603-21	16.6	128
272	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin□ lymphoma. *New England Journal of Medicine*, **2015**, 372, 311-9	59.2	2513
271	OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. *Journal of Immunology*, **2015**, 194, 125-133	5.3	57
270	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. *Journal of Thoracic Oncology*, **2015**, 10, 1726-35	8.9	155
269	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. *Oncotarget*, **2015**, 6, 4704-16	3.3	92
268	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study **2015**, 3, 3		63
267	Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. *JAMA Oncology*, **2015**, 1, 653-61	13.4	336
266	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. *Clinical Therapeutics*, **2015**, 37, 764-82	3.5	360
265	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. *Cancer Immunology Research*, **2015**, 3, 1158-64	12.5	205
264	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. *Cancer Immunology Research*, **2015**, 3, 1308-15	12.5	96
263	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. *Annals of Oncology*, **2015**, 26, 812-817	10.3	202
262	Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. *Journal of Biological Chemistry*, **2015**, 290, 8110-20	5.4	96
261	Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation. *Journal of General Virology*, **2015**, 96, 1463-1477	4.9	11
260	The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. *Cancer Discovery*, **2015**, 5, 16-8	24.4	247

259	PD-1 Inhibits TCR Proximal Signaling By Sequestering SHP-2 Phosphatase and Facilitating Csk-Mediated Inhibitory Phosphorylation of Lck. *Blood*, **2015**, 126, 283-283	2.2	2
258	BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. *Oncotarget*, **2015**, 6, 19445-55	3.3	13
257	Immunotherapy advances for glioblastoma. *Neuro-Oncology*, **2014**, 16, 1441-58	1	136
256	Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. *Journal of Virology*, **2014**, 88, 2508-18	6.6	43
255	Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. *Journal of Experimental Medicine*, **2014**, 211, 1905-18	16.6	151
254	Comment on "Tim-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection". *Journal of Immunology*, **2014**, 193, 467	5.3	5
253	RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. *Journal of Experimental Medicine*, **2014**, 211, 943-59	16.6	182
252	Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. *Cancer Cell*, **2014**, 25, 590-604	24.3	273
251	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. *Blood*, **2014**, 123, 3988-98	2.2	144
250	Inclusion of CD80 in HSV targets the recombinant virus to PD-L1 on DCs and allows productive infection and robust immune responses. *PLoS ONE*, **2014**, 9, e87617	3.7	18
249	CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. *Cell Reports*, **2014**, 9, 1075-88	10.6	181
248	Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response. *Cancer Research*, **2014**, 74, 633-4; discussion 635	10.1	36
247	IT-29IMMUNE CHECKPOINT BLOCKADE FOR GLIOBLASTOMA: PRECLINICAL ACTIVITY OF SINGLE AGENT AND COMBINATORIAL THERAPY. *Neuro-Oncology*, **2014**, 16, v116-v116	1	78
246	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. *Nature*, **2014**, 515, 577-81	50.4	1331
245	PD-L1 expression in nonclear-cell renal cell carcinoma. *Annals of Oncology*, **2014**, 25, 2178-2184	10.3	202
244	Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. *American Journal of Surgical Pathology*, **2014**, 38, 1715-23	6.7	117
243	Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. *Cancer Immunology Research*, **2014**, 2, 643-54	12.5	190
242	Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. *Gastroenterology*, **2014**, 146, 550-61	13.3	71

241	Actionable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. *Blood*, **2014**, 124, 74-74	2.2	2
240	PD-L1 expression in non-clear cell renal cell carcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 424-424	2.2	3
239	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. *Journal of Clinical Oncology*, **2014**, 32, 467-467	2.2	12
238	CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. *Cancer Immunology, Immunotherapy*, **2013**, 62, 347-57	7.4	21
237	Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. *Cancer Research*, **2013**, 73, 3591-603	10.1	475
236	PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. *Clinical Cancer Research*, **2013**, 19, 3462-73	12.9	601
235	DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8+ T cells independently of PD-1 and PD-L1. *International Immunology*, **2013**, 25, 651-60	4.9	16
234	T-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell death. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 414-25.e6	11.5	21
233	Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. *Cancer Discovery*, **2013**, 3, 1355-63	24.4	831
232	Increased T-bet is associated with senescence of influenza virus-specific CD8 T cells in aged humans. *Journal of Leukocyte Biology*, **2013**, 93, 825-36	6.5	51
231	Inadequate T follicular cell help impairs B cell immunity during HIV infection. *Nature Medicine*, **2013**, 19, 494-9	50.5	286
230	Costimulatory genes: hotspots of conflict between host defense and autoimmunity. *Immunity*, **2013** , 38, 1083-5	32.3	5
229	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. *Expert Review of Vaccines*, **2013**, 12, 597-615	5.2	49
228	TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. *PLoS Pathogens*, **2013**, 9, e1003232	7.6	223
227	Strength of PD-1 signaling differentially affects T-cell effector functions. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E2480-9	11.5	192
226	Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade. *OncoImmunology*, **2013**, 2, e25912	7.2	7
225	PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. *Journal of Clinical Investigation*, **2013**, 123, 2604-15	15.9	174
224	Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. *Cancer Research*, **2013**, 73, 6900-12	10.1	207

223	Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 15001-6	11.5	134
222	TIM-4, expressed by medullary macrophages, regulates respiratory tolerance by mediating phagocytosis of antigen-specific T cells. *Mucosal Immunology*, **2013**, 6, 580-90	9.2	33
221	Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. *Blood*, **2013**, 122, 3062-73	2.2	141
220	Down-regulation of CTLA-4 by HIV-1 Nef protein. *PLoS ONE*, **2013**, 8, e54295	3.7	19
219	CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival. *PLoS ONE*, **2013**, 8, e60391	3.7	18
218	PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. *PLoS ONE*, **2013**, 8, e77780	3.7	75
217	Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. **2013**,		21
216	Distinct Roles Of PD-1 Itsm and ITIM In Regulating Interactions With SHP-2, ZAP-70 and Lck, and PD-1-Mediated Inhibitory Function. *Blood*, **2013**, 122, 191-191	2.2	6
215	Anti-Programmed Death 1 (PD1) **2013**, 1-10		
214	Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model. *Blood*, **2013**, 122, 292-292	2.2	
213	JAK1 and JAK2 Modulate Tumor Cell Susceptibility To Natural Killer (NK) Cells Through Regulation Of PDL1 Expression. *Blood*, **2013**, 122, 3472-3472	2.2	1
212	Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. *Cell*, **2012**, 148, 739-51	56.2	111
211	Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses. *European Journal of Immunology*, **2012**, 42, 2343-53	6.1	23
210	Binding of hepatitis A virus to its cellular receptor 1 inhibits T-regulatory cell functions in humans. *Gastroenterology*, **2012**, 142, 1516-25.e3	13.3	41
209	Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. *Journal of Immunology*, **2012**, 189, 3936-46	5.3	19
208	PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. *Journal of Clinical Investigation*, **2012**, 122, 1712-6	15.9	114
207	Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. *Immunity*, **2011**, 35, 285-98	32.3	114
206	Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. *Blood*, **2011**, 118, 965-74	2.2	119

205	Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of □-iduronidase in mice with mucopolysaccharidosis type I. *Molecular Therapy*, **2011**, 19, 450-60	11.7	77
204	Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 21182-7	11.5	131
203	4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. *Journal of Immunology*, **2011**, 187, 1634-42	5.3	72
202	Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. *Journal of Immunology*, **2011**, 186, 4200-12	5.3	168
201	Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. *Journal of Leukocyte Biology*, **2011**, 89, 507-15	6.5	75
200	The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. *Journal of Immunology*, **2011**, 187, 1097-105	5.3	128
199	The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. *Journal of Immunology*, **2011**, 187, 1113-9	5.3	99
198	Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 1100-7	9.4	118
197	The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. *Journal of Virology*, **2011**, 85, 4184-97	6.6	87
196	A polymorphism in TIM1 is associated with susceptibility to severe hepatitis A virus infection in humans. *Journal of Clinical Investigation*, **2011**, 121, 1111-8	15.9	59
195	Ex Vivo Expansion of Donor-Derived Anti-Tumor T Cells for CLL-Specific Adoptive Immunotherapy. *Blood*, **2011**, 118, 978-978	2.2	
194	Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. *Nature Medicine*, **2010**, 16, 1147-51	50.5	344
193	TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. *Immunological Reviews*, **2010**, 235, 172-89	11.3	422
192	Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation **2010**, 51, 3418-23		50
191	TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigen-specific T cells. *Journal of Immunology*, **2010**, 185, 6839-49	5.3	68
190	Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. *Journal of Immunology*, **2010**, 184, 476-87	5.3	40
189	Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. *Journal of Virology*, **2010**, 84, 2078-89	6.6	92
188	Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 14733-8	11.5	555

187	T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. *Journal of Immunology*, **2010**, 184, 1918-30	5.3	213
186	PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity. *Journal of Investigative Dermatology*, **2010**, 130, 2222-30	4.3	24
185	Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivity. *Journal of Immunology*, **2010**, 185, 5225-35	5.3	59
184	PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. *Mucosal Immunology*, **2010**, 3, 81-91	9.2	133
183	The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms. *Human Pathology*, **2010**, 41, 1486-94	3.7	25
182	Role of PD-1 in regulating acute infections. *Current Opinion in Immunology*, **2010**, 22, 397-401	7.8	104
181	Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. *Journal of Clinical Investigation*, **2010**, 120, 3855-68	15.9	41
180	Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. *Journal of Clinical Investigation*, **2010**, 120, 3878-90	15.9	96
179	Marrow-Infiltrating T Cells In Patients with Chronic Lymphocytic Leukemia Display Markers of Functional Impairment and Express PD-1. *Blood*, **2010**, 116, 2417-2417	2.2	
178	Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. *Ocular Immunology and Inflammation*, **2009**, 17, 47-55	2.8	32
177	Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. *Journal of Immunology*, **2009**, 182, 2102-12	5.3	93
176	Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. *Journal of Virology*, **2009**, 83, 7305-21	6.6	216
175	Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells **2009**, 50, 4941-8		15
174	Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. *Journal of Immunology*, **2009**, 183, 7898-908	5.3	55
173	Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. *PLoS Pathogens*, **2009**, 5, e1000313	7.6	273
172	Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 10734-9	11.5	59
171	Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection. *Journal of Virology*, **2009**, 83, 9068-78	6.6	16
170	Enhancing SIV-specific immunity in vivo by PD-1 blockade. *Nature*, **2009**, 458, 206-10	50.4	601

169	Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. *Nature Immunology*, **2009**, 10, 29-37	19.1	1403
168	The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. *Immunological Reviews*, **2009**, 229, 244-58	11.3	203
167	PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *Journal of Experimental Medicine*, **2009**, 206, 3015-29	16.6	1384
166	CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. *Nature Immunology*, **2008**, 9, 176-85	19.1	241
165	Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. *Clinical Immunology*, **2008**, 126, 140-7	9	46
164	Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. *Gastroenterology*, **2008**, 134, 1927-37, 1937.e1-2	13.3	226
163	Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 10275-6	11.5	45
162	Interaction of human PD-L1 and B7-1. *Molecular Immunology*, **2008**, 45, 3567-72	4.3	184
161	High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. *Journal of Virology*, **2008**, 82, 3154-60	6.6	159
160	Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. *Journal of Virology*, **2008**, 82, 9808-22	6.6	79
159	Simian immunodeficiency virus (SIV)-specific CD8+ T-cell responses in vervet African green monkeys chronically infected with SIVagm. *Journal of Virology*, **2008**, 82, 11577-88	6.6	32
158	IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20428-33	11.5	154
157	ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. *Journal of Immunology*, **2008**, 180, 5448-56	5.3	66
156	Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 15016-21	11.5	349
155	Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. *Journal of Experimental Medicine*, **2008**, 205, 543-55	16.6	184
154	The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 2658-63	11.5	85
153	Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. *Journal of Virology*, **2008**, 82, 5109-14	6.6	36
152	Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. *Blood*, **2008**, 112, 2149-55	2.2	54

151	Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. *Blood*, **2008**, 112, 1662-72	2.2	49
150	Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. *Blood*, **2008**, 112, 3679-87	2.2	67
149	PD-1 and its ligands in tolerance and immunity. *Annual Review of Immunology*, **2008**, 26, 677-704	34.7	3557
148	PD-1 negatively regulates CD8 T cell-mediated mucosal autoimmunity. *FASEB Journal*, **2008**, 22, 852.4	0.9	
147	PD-L1 interaction limits excessive Th1 effector function during Mycobacterium tuberculosis infection. *FASEB Journal*, **2008**, 22, 663.20	0.9	
146	In-fusion assembly: seamless engineering of multidomain fusion proteins, modular vectors, and mutations. *BioTechniques*, **2007**, 43, 354-9	2.5	188
145	The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. *Nature Immunology*, **2007**, 8, 239-45	19.1	1048
144	Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. *Nature Immunology*, **2007**, 8, 1246-54	19.1	411
143	Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 15430-5	11.5	184
142	A novel alloantigen-specific CD8+PD1+ regulatory T cell induced by ICOS-B7h blockade in vivo. *Journal of Immunology*, **2007**, 179, 786-96	5.3	35
141	Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. *Journal of Virology*, **2007**, 81, 2545-53	6.6	386
140	PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. *Journal of Immunology*, **2007**, 178, 2714-20	5.3	196
139	The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. *Journal of Immunology*, **2007**, 179, 3672-9	5.3	88
138	Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. *Circulation*, **2007**, 116, 2062-71	16.7	164
137	Immunoglobulin A (IgA) is a natural ligand of hepatitis A virus cellular receptor 1 (HAVCR1), and the association of IgA with HAVCR1 enhances virus-receptor interactions. *Journal of Virology*, **2007**, 81, 3437-46	6.6	45
136	Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. *Journal of Virology*, **2007**, 81, 5819-28	6.6	110
135	PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. *Journal of Immunology*, **2007**, 179, 5064-70	5.3	179
134	Twisted gastrulation (Tsg) is regulated by Tob and enhances TGF-beta signaling in activated T lymphocytes. *Blood*, **2007**, 109, 2944-52	2.2	11

133	PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. *Aids*, **2007**, 21, 2005-13	3.5	131
132	Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. *Immunity*, **2007**, 27, 111-22	32.3	1206
131	TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. *Immunity*, **2007**, 27, 927-40	32.3	461
130	Structures of T cell immunoglobulin mucin protein 4 show a metal-Ion-dependent ligand binding site where phosphatidylserine binds. *Immunity*, **2007**, 27, 941-51	32.3	176
129	The ICOS-ligand B7-H2, expressed on human type II alveolar epithelial cells, plays a role in the pulmonary host defense system. *European Journal of Immunology*, **2006**, 36, 906-18	6.1	27
128	PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. *European Journal of Immunology*, **2006**, 36, 58-64	6.1	66
127	Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation. *Journal of Immunology*, **2006**, 176, 7263-71	5.3	89
126	Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. *Journal of Experimental Medicine*, **2006**, 203, 2223-7	16.6	333
125	Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. *Journal of Immunology*, **2006** , 177, 4196-202	5.3	132
124	Tissue expression of PD-L1 mediates peripheral T cell tolerance. *Journal of Experimental Medicine*, **2006**, 203, 883-95	16.6	875
123	Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. *Blood*, **2006**, 107, 1528-36	2.2	130
122	Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. *American Journal of Surgical Pathology*, **2006**, 30, 802-10	6.7	285
121	Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature*, **2006**, 439, 682-7	50.4	2903
120	PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature*, **2006**, 443, 350-4	50.4	2001
119	Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). *Blood*, **2005**, 105, 3372-80	2.2	104
118	The B7 family revisited. *Annual Review of Immunology*, **2005**, 23, 515-48	34.7	1861
117	TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. *Nature Immunology*, **2005**, 6, 447-54	19.1	252
116	Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo. *Journal of Immunology*, **2005**, 175, 3133-9	5.3	30

115	Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. *Journal of Immunology*, **2005**, 175, 7372-9	5.3	105
114	CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. *Journal of Immunology*, **2005**, 175, 1558-65	5.3	110
113	CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. *Journal of Experimental Medicine*, **2004**, 199, 1479-89	16.6	365
112	PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10691-6	11.5	474
111	Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. *Nature Immunology*, **2004**, 5, 1149-56	19.1	262
110	PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. *Cellular Immunology*, **2004**, 230, 89-98	4.4	60
109	RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. *Developmental Cell*, **2004**, 7, 585-95	10.2	332
108	An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. *Immunity*, **2004**, 20, 563-75	32.3	180
107	Rap1-GTP Promotes the Generation of Regulatory T Cells in Vivo.. *Blood*, **2004**, 104, 110-110	2.2	1
106	The E3 Ubiquitin Ligase TRIM36, a Transcriptional Target of Tob, Is Expressed in Anergic T Cells and Mediates Unresponsiveness through Proteolysis of Signaling Proteins PLC-? and PKC-?.. *Blood*, **2004**, 104, 113-113	2.2	1
105	CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. *Novartis Foundation Symposium*, **2003**, 252, 67-88; discussion 88-91, 106-14		59
104	Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. *Journal of Immunology*, **2003**, 170, 1257-66	5.3	731
103	The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. *Journal of Biological Chemistry*, **2003**, 278, 21930-7	5.4	87
102	Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. *European Journal of Immunology*, **2003**, 33, 2706-16	6.1	456
101	Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. *European Journal of Immunology*, **2003**, 33, 3117-26	6.1	350
100	Immunology: hepatitis A virus link to atopic disease. *Nature*, **2003**, 425, 576	50.4	157
99	Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. *Nature Immunology*, **2003**, 4, 1102-10	19.1	486
98	The TIM gene family: emerging roles in immunity and disease. *Nature Reviews Immunology*, **2003**, 3, 454-62	32.5	326

97	The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. *Journal of Clinical Investigation*, **2003**, 112, 234-43	15.9	40
96	The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. *Journal of Clinical Investigation*, **2003**, 112, 234-243	15.9	107
95	PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. *European Journal of Immunology*, **2002**, 32, 634-43	6.1	523
94	Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. *Nature*, **2002**, 415, 536-41	50.4	1120
93	Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. *Nature Medicine*, **2002**, 8, 1024-32	50.5	672
92	The B7-CD28 superfamily. *Nature Reviews Immunology*, **2002**, 2, 116-26	36.5	1314
91	Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. *Immunology Letters*, **2002**, 84, 57-62	4.1	216
90	Cutting edge: CD94/NKG2 is expressed on Th1 but not Th2 cells and costimulates Th1 effector functions. *Journal of Immunology*, **2002**, 169, 5382-6	5.3	24
89	Critical role of CD81 in cognate T-B cell interactions leading to Th2 responses. *International Immunology*, **2002**, 14, 513-23	4.9	65
88	Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. *Microcirculation*, **2002**, 9, 133-45	2.9	138
87	Expression and Regulation of the PD-L1 Immunoinhibitory Molecule on Microvascular Endothelial Cells. *Microcirculation*, **2002**, 9, 133-145	2.9	183
86	Characterization of endogenous Chinese hamster ovary cell surface molecules that mediate T cell costimulation. *Cellular Immunology*, **2001**, 213, 83-93	4.4	13
85	PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nature Immunology*, **2001**, 2, 261-8	19.1	2040
84	Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. *Nature Immunology*, **2001**, 2, 1174-82	19.1	221
83	Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. *Nature Immunology*, **2001**, 2, 1109-16	19.1	404
82	ICOS is critical for CD40-mediated antibody class switching. *Nature*, **2001**, 409, 102-5	50.4	550
81	CD4+CD25high regulatory cells in human peripheral blood. *Journal of Immunology*, **2001**, 167, 1245-53	5.3	1517
80	Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 9778-83	11.5	59

79	B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. *Journal of Clinical Investigation*, **2001**, 107, 881-7	15.9	70
78	. *Applied Immunohistochemistry & Molecular Morphology*, **2000**, 8, 210-215		23
77	p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. *Nature Medicine*, **2000**, 6, 290-7	50.5	205
76	Intercellular adhesion molecule 1 is critical for activation of CD28-deficient T cells. *Journal of Immunology*, **2000**, 165, 6091-8	5.3	59
75	Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *Journal of Experimental Medicine*, **2000**, 192, 1027-34	16.6	3501
74	Examination of CD8+ T cell function in humans using MHC class I tetramers: similar cytotoxicity but variable proliferation and cytokine production among different clonal CD8+ T cells specific to a single viral epitope. *Journal of Immunology*, **2000**, 165, 6214-20	5.3	61
73	Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. *Journal of Immunology*, **2000**, 165, 5035-40	5.3	365
72	PTPROt: An Alternatively Spliced and Developmentally Regulated B-Lymphoid Phosphatase That Promotes G0/G1 Arrest. *Blood*, **1999**, 94, 2403-2413	2.2	66
71	Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands. *International Immunology*, **1999**, 11, 407-16	4.9	35
70	B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. *Journal of Experimental Medicine*, **1999**, 189, 919-30	16.6	45
69	CD48-deficient mice have a pronounced defect in CD4(+) T cell activation. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 1019-23	11.5	81
68	Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. *Immunity*, **1999**, 11, 689-98	32.3	266
67	No evidence for MUC 1-induced apoptosis. *Nature Medicine*, **1998**, 4, 1093	50.5	3
66	The murine Cd48 gene: allelic polymorphism in the IgV-like region. *International Journal of Immunogenetics*, **1998**, 25, 421-3		4
65	The leukocyte semaphorin CD100 is expressed in most T-cell, but few B-cell, non-Hodgkin's lymphomas. *American Journal of Pathology*, **1998**, 153, 255-62	5.8	30
64	B7 (CD80 and CD86) **1998**, 304-308		1
63	Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 11336-41	11.5	115
62	Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. *Journal of Immunology*, **1998**, 160, 1532-8	5.3	149

61	The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion. *International Immunology*, **1997**, 9, 805-13	4.9	29
60	The human semaphorin-like leukocyte cell surface molecule CD100 associates with a serine kinase activity. *Journal of Biological Chemistry*, **1997**, 272, 23515-20	5.4	45
59	Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. *Science*, **1997**, 278, 124-8	33.3	389
58	B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. *Immunity*, **1997**, 6, 303-13	32.3	438
57	Ex Vivo Generation of Human Anti-Pre-B Leukemia-Specific Autologous Cytolytic T Cells. *Blood*, **1997**, 90, 549-561	2.2	113
56	CD101 is expressed by skin dendritic cells. Role in T-lymphocyte activation. *Tissue Antigens*, **1997**, 50, 439-48		10
55	The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3. *Mammalian Genome*, **1997**, 8, 581-2	3.2	14
54	Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. *British Journal of Haematology*, **1997**, 97, 409-17	4.5	95
53	Ex Vivo Generation of Human Anti-Pre-B Leukemia-Specific Autologous Cytolytic T Cells. *Blood*, **1997**, 90, 549-561	2.2	6
52	In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation. *Blood*, **1997**, 90, 4297-4306	2.2	4
51	Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4. *Journal of Immunology*, **1997**, 159, 4799-805	5.3	36
50	Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 11780-5	11.5	219
49	The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. *Immunological Reviews*, **1996**, 153, 5-26	11.3	143
48	Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. *Nature Medicine*, **1996**, 2, 1367-70	50.5	151
47	A cell type-specific enhancer in the human B7.1 gene regulated by NF-kappaB. *Journal of Experimental Medicine*, **1996**, 183, 777-89	16.6	76
46	Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. *Journal of Experimental Medicine*, **1996**, 184, 365-76	16.6	79
45	B7-Deficient Mice Reveal an Alternative Functional CTLA-4 Counterreceptor **1996**, 107-120		
44	The Regulatory Functions of Co-Stimulators Revealed in Transgenic Mice **1996**, 101-106		

43	Activation of human T cell lymphotropic virus type I-infected T cells is independent of B7 costimulation. *Journal of Immunology*, **1996**, 157, 2932-8	5.3	7
42	Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. *International Immunology*, **1995**, 7, 957-66	4.9	69
41	B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. *Immunity*, **1995**, 2, 523-32	32.3	493
40	CTLA4 mediates antigen-specific apoptosis of human T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 811-5	11.5	290
39	Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 8200-4	11.5	183
38	Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. *Transplantation*, **1995**, 60, 1171-8	1.8	127
37	Human alveolar macrophages present antigen ineffectively due to defective expression of B7 costimulatory cell surface molecules. *Journal of Clinical Investigation*, **1995**, 95, 1415-21	15.9	123
36	Induction of Alloantigen Specific T Cell Anergy by Inhibition of the B7: CD28 Pathway **1995**, 205-218		
35	Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 3137-41	11.5	144
34	CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. *Journal of Experimental Medicine*, **1994**, 180, 1665-73	16.6	96
33	Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. *Science*, **1994**, 266, 1039-42	33.3	286
32	Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. *Current Opinion in Immunology*, **1994**, 6, 797-807	7.8	127
31	CTLA-4 can function as a negative regulator of T cell activation. *Immunity*, **1994**, 1, 405-13	32.3	1697
30	Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 7663-7	11.5	250
29	Identification, by protein sequencing and gene transfection, of sgp-60 as the murine homologue of CD48. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 3418-22	11.5	12
28	B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. *Journal of Experimental Medicine*, **1993**, 178, 1753-63	16.6	187
27	Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. *Journal of Experimental Medicine*, **1993**, 178, 2185-92	16.6	308
26	Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. *Science*, **1993**, 262, 907-9	33.3	326

25	Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. *Science*, **1993**, 262, 909-11	33.3	793
24	Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 11059-63	11.5	187
23	Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 5687-90	11.5	238
22	Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 6586-90	11.5	468
21	Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. *European Journal of Immunology*, **1993**, 23, 283-6	6.1	42
20	The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T cell activation and adhesion. *Cellular Immunology*, **1993**, 152, 249-60	4.4	48
19	The HB-6, CDw75, and CD76 differentiation antigens are unique cell-surface carbohydrate determinants generated by the beta-galactoside alpha 2,6-sialyltransferase. *Journal of Cell Biology*, **1992**, 116, 423-35	7.3	98
18	Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 4210-4	11.5	187
17	Early signaling defects in human T cells anergized by T cell presentation of autoantigen. *Journal of Experimental Medicine*, **1992**, 176, 177-86	16.6	127
16	Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. *Journal of Experimental Medicine*, **1992**, 175, 951-60	16.6	107
15	Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 271-5	11.5	120
14	Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. *Nature*, **1992**, 360, 266-8	50.4	258
13	Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. *Cellular Immunology*, **1991**, 137, 429-37	4.4	283
12	Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. *New England Journal of Medicine*, **1991**, 325, 1525-33	59.2	566
11	Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. *Journal of Experimental Medicine*, **1991**, 174, 625-31	16.6	298
10	B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 6575-9	11.5	375
9	Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. *Journal of Experimental Medicine*, **1989**, 170, 145-61	16.6	274
8	Activation primes human B lymphocytes to respond to heat shock. *Journal of Experimental Medicine* , **1989**, 170, 1763-8	16.6	28

7	Expression and regulation of CD5 on in vitro activated human B cells. *European Journal of Immunology*, **1989**, 19, 849-55	6.1	59
6	Definition of T-cell specific DNA-binding factors that interact with a 3Psilencer in the CD4+ T-cell gene Rpt-1. *Gene*, **1989**, 85, 461-9	3.8	2
5	Isolated human follicular dendritic cells display a unique antigenic phenotype. *Journal of Experimental Medicine*, **1989**, 169, 2043-58	16.6	207
4	Interleukin 6 gene expression in normal and neoplastic B cells. *Journal of Clinical Investigation*, **1989** , 83, 1512-8	15.9	117
3	Cloning of Ly-5 cDNA. *Proceedings of the National Academy of Sciences of the United States of America*, **1985**, 82, 7360-3	11.5	109
2	Mapping temperature-sensitive mutants of vesicular stomatitis virus by RNA heteroduplex formation. *Journal of General Virology*, **1981**, 57, 103-17	4.9	15
1	RNA synthesis of vesicular stomatitis virus. VIII. Oligonucleotides of the structural genes and mRNA. *Gene*, **1979**, 5, 141-57	3.8	29